RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+12%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$3.07B
AUM Growth
+$3.07B
(-7.2%)
Cap. Flow
-$383M
Cap. Flow
% of AUM
-12.45%
Top 10 Holdings %
Top 10 Hldgs %
34.44%
Holding
116
New
6
Increased
34
Reduced
30
Closed
6
Top Buys
| 1 |
Summit Therapeutics
SMMT
|
$22.8M |
| 2 |
Eli Lilly
LLY
|
$18.2M |
| 3 |
Nuvalent
NUVL
|
$17.8M |
| 4 |
ZBIO
Zenas BioPharma, Inc. Common Stock
ZBIO
|
$14.9M |
| 5 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$11.4M |
Top Sells
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$156M |
| 2 |
Idexx Laboratories
IDXX
|
$58.2M |
| 3 |
Evolent Health
EVH
|
$56.8M |
| 4 |
Boston Scientific
BSX
|
$30M |
| 5 |
Acadia Healthcare
ACHC
|
$23M |
Sector Composition
| 1 | Healthcare | 97.81% |
| 2 | Consumer Staples | 1.99% |
| 3 | Industrials | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
UnitedHealth
UNH
$281B
| $172M | 5.6% | 294,250 +19,250 | +7% | +$11.3M |
|
2
Intuitive Surgical
ISRG
$170B
| $133M | 4.32% | 270,000 -28,500 | -10% | -$14M |
|
3
argenx
ARGX
$43.6B
| $127M | 4.12% | 233,500 +4,250 | +2% | +$2.3M |
|
|
4
Eli Lilly
LLY
$657B
| $126M | 4.09% | 142,000 +20,500 | +17% | +$18.2M |
|
5
Ultragenyx Pharmaceutical
RARE
$2.89B
| $110M | 3.58% | 1,978,272 +54,200 | +3% | +$3.01M |
|
6
Neurocrine Biosciences
NBIX
$13.8B
| $108M | 3.52% | 939,000 -1,000 | -0.1% | -$115K |
|
7
Exact Sciences
EXAS
$8.98B
| $78.2M | 2.54% | 1,147,500 +66,000 | +6% | +$4.5M |
|
|
BPMC
8
DELISTED
Blueprint Medicines
BPMC
| $71.1M | 2.31% | 768,776 -1,691,641 | -69% | -$156M |
|
9
Alnylam Pharmaceuticals
ALNY
$58.5B
| $68.8M | 2.24% | 250,000 | – | – |
|
10
Travere Therapeutics
TVTX
$1.56B
| $65.5M | 2.13% | 4,684,476 +202,211 | +5% | +$2.83M |
|
11
Rhythm Pharmaceuticals
RYTM
$6.85B
| $64.3M | 2.09% | 1,228,093 -52,400 | -4% | -$2.75M |
|
12
Mirum Pharmaceuticals
MIRM
$3.71B
| $61.6M | 2.01% | 1,580,488 -191,550 | -11% | -$7.47M |
|
13
Freshpet
FRPT
$2.72B
| $61.1M | 1.99% | 446,500 -33,500 | -7% | -$4.58M |
|
|
14
Evolent Health
EVH
$1.12B
| $58.5M | 1.9% | 2,070,000 -2,007,500 | -49% | -$56.8M |
|
15
Madrigal Pharmaceuticals
MDGL
$9.76B
| $55.8M | 1.82% | 263,062 +17,563 | +7% | +$3.73M |
|
16
Phreesia
PHR
$1.88B
| $52M | 1.69% | 2,282,500 -135,000 | -6% | -$3.08M |
|
17
Xenon Pharmaceuticals
XENE
$2.98B
| $51.8M | 1.69% | 1,316,477 +43,600 | +3% | +$1.72M |
|
|
18
Acadia Healthcare
ACHC
$2.12B
| $51.7M | 1.68% | 815,000 -362,500 | -31% | -$23M |
|
19
Penumbra
PEN
$10.6B
| $51.5M | 1.68% | 265,000 | – | – |
|
20
West Pharmaceutical
WST
$17.8B
| $50.4M | 1.64% | 167,750 +22,250 | +15% | +$6.68M |
|
21
Insmed
INSM
$28.8B
| $49.9M | 1.62% | 683,344 -125,012 | -15% | -$9.13M |
|
22
Kymera Therapeutics
KYMR
$2.95B
| $49.7M | 1.62% | 1,049,386 -114,587 | -10% | -$5.42M |
|
23
Ascendis Pharma
ASND
$11.8B
| $48.5M | 1.58% | 325,000 +35,000 | +12% | +$5.23M |
|
24
Humana
HUM
$36.5B
| $46.9M | 1.53% | 148,000 +592 | +0.4% | +$188K |
|
25
Structure Therapeutics
GPCR
$1.11B
| $46.7M | 1.52% | 1,063,910 +64,048 | +6% | +$2.81M |
|